Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 56,664 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 56,664 shares of the specialty pharmaceutical company's stock, valued at approximately $3,794,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.26% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ANIP. Allianz Asset Management GmbH purchased a new position in shares of ANI Pharmaceuticals during the 1st quarter worth approximately $415,000. Victory Capital Management Inc. raised its holdings in shares of ANI Pharmaceuticals by 22.4% in the 1st quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company's stock valued at $1,129,000 after purchasing an additional 3,086 shares in the last quarter. Hohimer Wealth Management LLC grew its position in shares of ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after buying an additional 247 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of ANI Pharmaceuticals by 31.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 6,457 shares of the specialty pharmaceutical company's stock valued at $432,000 after buying an additional 1,527 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of ANI Pharmaceuticals by 68.3% in the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock valued at $10,565,000 after buying an additional 64,021 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In other news, insider Christopher Mutz sold 4,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the completion of the sale, the insider directly owned 107,317 shares of the company's stock, valued at $6,487,312.65. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Ori Gutwerg sold 881 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president directly owned 89,897 shares in the company, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock valued at $345,222 over the last three months. 11.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Price Performance

ANIP traded up $0.20 on Friday, reaching $63.55. The company had a trading volume of 80,334 shares, compared to its average volume of 320,052. The company has a fifty day moving average of $63.88 and a 200-day moving average of $63.33. The company has a market capitalization of $1.38 billion, a P/E ratio of -50.14 and a beta of 0.57. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 3.12% and a positive return on equity of 21.35%. The company had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the firm posted $0.82 EPS. The business's revenue for the quarter was up 43.4% on a year-over-year basis. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on ANIP shares. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Guggenheim reiterated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright initiated coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $84.00 price target on the stock. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $78.88.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.